Mumbai, Dec. 3 -- The formulation has been developed using the company's proprietary drug delivery technologies, combining naproxen delayed-release minitablets and esomeprazole pellets in a single hard gelatin capsule. Zim said the platform offers a differentiated, patient-friendly delivery system and forms part of its New Innovative Product (NIP) pipeline.

The FDC is indicated for adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for reducing the risk of NSAID-associated gastric and duodenal ulcers.

Zim Laboratories stated that the approval strengthens its presence in the pain-management and gastro-protective segments. The company has already signed a commercial supply agreeme...